ArticleEJNMMI research2011

Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors.

Caroline Rousseau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.